Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma

T cells modified to express chimeric antigen receptor (CAR) targeting CD19 (CD19CAR) have produced remarkable clinical responses in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. CD19CAR T-cell therapy has also demonstrated prominent effects in B-cell non-Hodgkin lymphoma (B-...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Köksal, Hakan, Dillard, Pierre, Josefsson, Sarah E., Maggadottir, Solrun Melkorka, Pollmann, Sylvie, Fåne, Anne, Blaker, Yngvild Nuvin, Beiske, Klaus, Huse, Kanutte, Kolstad, Arne, Holte, Harald, Kvalheim, Gunnar, Smeland, Erlend B., Myklebust, June H., Inderberg, Else Marit, Wälchli, Sébastien
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2019
Soggetti:
Immunobiology and Immunotherapy
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6482360/
https://ncbi.nlm.nih.gov/pubmed/30979721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018029678
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi